TerminatedPhase 1NCT03519984

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

Studying Acute myeloid leukemia with t(9;22)(q34.1;q11.2)

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Southern California
Principal Investigator
Akil Merchant, MD, MD
University of Southern California
Intervention
Cytarabine(drug)
Enrollment
3 enrolled
Eligibility
18 years · All sexes
Timeline
20182020

Study locations (1)

Collaborators

National Cancer Institute (NCI) · Vasgene Therapeutics, Inc · Whittier Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03519984 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia with t(9;22)(q34.1;q11.2)

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia with t(9;22)(q34.1;q11.2)

← Back to all trials